Knowledge-Based Firm in Iran Conducts Clinical Test on Blood Coagulant Powder, Anticancer Substances
"We have found a method to use blood coagulant powder and MOF materials which cause blood to clot to prevent cancer," Omid Mahmoudi, a master's student in chemical engineering, a doctoral student and the chairman of the board of directors of Fateh Shimi Setareh Pars company, told ANA.
“We have also succeeded in producing nano-based MOF type 3 products and a device in the field of water and wastewater treatment. The fields of application of our products are medical industry, nuclear industries, electronics industries, and water and wastewater treatment. Our company's field of activity is production of MOF nanomaterials, nanoalcohol, and smart water and wastewater treatment devices,” he added.
Mahmoudi explained that in the medical sector, the specialists at his company have carried out activities in the field of blood coagulant drug (powder) and MOF anti-cancer substances to clot blood without complications, adding that they are still in the clinical trial stage.
In a relevant development earlier this year, Iranian scientists at Kharazmi University fabricated photonic sensors for blood glucose measurement and are making efforts to commercialize the product.
“Our main field of activity is development of a photonic platform for measuring oxygen and blood sugar for application in the medical areas, and we are more focused on using this platform to measure blood sugar in people with diabetes,” said Esmayeel Heydari, a faculty member of Kharazmi University.
“We want to measure blood glucose in real time and in a continuous manner. One of our long-term goals is to help the diabetic patients measure their blood sugar in the long term by sensors implanted under their skin,” he added.
“We are commercializing a part of this platform and we received a knowledge-based certificate for a blood oxygen measurement sensor,” Heydari said.
4155/v
